Astrazeneca Oxford

Rediff.com » News » Astrazeneca Oxford

News for Astrazeneca Oxford

News
Business

AstraZeneca's COVID-19 Vaccine: The TTS Factor

'It is admitted that the AZ vaccine can, in very rare cases, cause TTS.' IMAGE: A vial labelled 'AstraZeneca COVID-19 Vaccine'. Photograph: Illustration/Dado Ruvic/Reuters The controversial......

Oxford-AstraZeneca Covid jab faces legal threat in UK over side effects: Report

The Oxford-AstraZeneca COVID-19 vaccine, known as Vaxzevria in Europe and licensed as Covishield in India, is facing a legal challenge in the high court in London, a UK media report said on......

AstraZeneca admits in court: Covishield causes TTS

United Kingdom-headquartered pharmaceutical giant AstraZeneca (AZ) has admitted that in 'very rare cases' its Covid vaccine can cause a blood clot related side effect but the causal link is......

Oxford, AstraZeneca COVID-19 vaccine trials resume in UK

Biopharmaceutical giant AstraZeneca and the University of Oxford on Saturday said that clinical trials for their coronavirus vaccine have resumed in the United Kingdom after the Medicines Health......

AstraZeneca reaffirms Covid vaccine safety amid rare TTS concerns

In light of recent concerns surrounding potential rare side effects of the AstraZeneca-Oxford COVID-19 vaccine, the pharmaceutical giant has reiterated its commitment to patient safety while......

Serum Institute to start phase-2 trials of Oxford-AstraZeneca vaccine

The institute expects to complete both, phase-2 and 3 trials in India by the end of this year. Pune's Serum Institute of India (SII) is all set to start phase-2 clinical trials of the Oxford......

'We will price Covid vaccine below Rs 1,000'

'Once the trials are successful in India and the UK, we are certain that COVISHIELD will be one of the first vaccines to be introduced.' IMAGE: The Reference Center for Special Immunobiologicals......

Meet Adar Poonawala, India's COVID-19 vaccine man

Serum Institute is investing $200 million to create capacities for the COVID-19 vaccine.Sohini Das profiles its 39-year-old CEO. IMAGE: Adar Poonawalla, right, and his father Dr Cyrus S......

Astrazeneca Oxford

News for Astrazeneca Oxford

AstraZeneca's COVID-19 Vaccine: The TTS Factor

Oxford-AstraZeneca Covid jab faces legal threat in UK over side effects: Report

AstraZeneca admits in court: Covishield causes TTS

Oxford, AstraZeneca COVID-19 vaccine trials resume in UK

AstraZeneca reaffirms Covid vaccine safety amid rare TTS concerns

Serum Institute to start phase-2 trials of Oxford-AstraZeneca vaccine

'We will price Covid vaccine below Rs 1,000'

Meet Adar Poonawala, India's COVID-19 vaccine man

Top Coverage News

World Test Championship 2023

Manipur's Tragedy

IPL 2023

Sri Lanka's Tour of India 2023

GUJARAT, HIMACHAL GO TO POLLS